Canada has approved and begun the pharmacy rollout of lower-cost generic versions of Ozempic and Wegovy this month [1].

This development marks a significant shift in access to semaglutide, the active ingredient used for diabetes and weight loss. While the U.S. continues to face high costs and supply shortages, Canada's move could lower the financial barrier for patients seeking these medications.

Health Canada approved the generics, allowing retail pharmacies across the country to begin dispensing the medication [1]. Canada is the first G7 nation to approve these lower-cost alternatives [1]. Some reports indicate that the potential cost for generic Ozempic or Wegovy could be as low as $15 per month [2].

The availability of these generics is expected to have a global impact. It is estimated that 40% of the world's population could have access to these generic versions within a year [2].

In contrast, the U.S. market remains restricted. The United States is currently blocked by patent protections and a slower regulatory pathway [1, 3]. These hurdles mean that generic versions of the drug are unlikely to be available in the U.S. until at least the end of 2031 [3].

"Americans are unlikely to see generic versions of semaglutide — the active ingredient in Novo Nordisk's Ozempic and Wegovy — until at least the end of 2031," NBC News said in a report cited by Becker's Hospital Review [3].

“Canada is the first G7 nation to approve these lower-cost alternatives.”

The divergence between Canadian and U.S. drug approvals highlights the impact of different patent enforcement and regulatory frameworks on public health. By bypassing the protections that keep Novo Nordisk's monopoly intact in the U.S., Canada is accelerating patient access to GLP-1 medications, potentially reducing the burden on its healthcare system and lowering individual patient spending.